Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA-DR is a cell surface receptor belonging to the major histocompatibility complex (MHC) class II family. It is primarily involved in presenting peptide antigens to the immune system, specifically to T-helper cells. While typically found on professional antigen-presenting cells, HLA-DR can also be expressed by non-immune epithelial cells under certain conditions, particularly in response to inflammatory stimuli on the ocular surface. Its expression level serves as a biomarker for ocular surface inflammation and disease severity, especially in dry eye disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Leukocyte Antigen – DR (HLA-DR).